Presentation, follow-up, and outcomes among African/Afro-Caribbean men on active surveillance for prostate cancer: experiences of a high-volume UK centre.
Aged
Black People
/ statistics & numerical data
Caribbean Region
Ethnicity
/ statistics & numerical data
Follow-Up Studies
Hospitals, High-Volume
/ statistics & numerical data
Humans
Male
Middle Aged
Prognosis
Prospective Studies
Prostatectomy
/ mortality
Prostatic Neoplasms
/ ethnology
Retrospective Studies
Risk Factors
Survival Rate
United Kingdom
Watchful Waiting
White People
/ statistics & numerical data
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
24
09
2020
accepted:
04
12
2020
revised:
10
11
2020
pubmed:
10
2
2021
medline:
19
1
2022
entrez:
9
2
2021
Statut:
ppublish
Résumé
Experiences of African/Afro-Caribbean men on active surveillance (AS) for prostate cancer (PCa) in the United Kingdom (UK) are not well documented. We compared follow-up appointments, adherence, and clinical outcomes among African/Afro-Caribbean men on AS at a high-volume UK hospital with other ethnicities. Men with confirmed low-intermediate risk Pca who attended the AS clinic (2005-2016) and had undergone ≥1 follow-up biopsy (n = 458) were included. Non-adherence (defined as >20% missed appointments), suspicion of disease progression (any upgrading, >30% positive cores, cT-stage > 3, PIRADS > 3), any upgrading from diagnostic biopsy and conversion to active treatment (prostatectomy, radiotherapy or hormone therapy) according to ethnicity (African/Afro-Caribbean versus other ethnicities) were assessed using multivariable regression analysis. Twenty-three percent of eligible men were recorded as African/Afro-Caribbean, while the remainder were predominantly Caucasian. African/Afro-Caribbean men had slightly lower PSA at diagnosis (median 5.0 vs. 6.0 ng/mL) and more positive cores at diagnosis (median 2 vs. 1). They had a substantially higher rate of non-attendance at scheduled follow-up visits (24% vs. 10%, p < 0.001). Adjusted analyses suggest African/Afro-Caribbean men may be at increased risk of disease progression (hazard ratio [HR]: 1.38; 95% confidence interval [CI] 0.99-1.91, P = 0.054) and upgrading (HR: 1.29; 95% CI 0.87-1.92, P = 0.305), though neither reached statistical significance. No difference in risk of conversion to treatment was observed between ethnic groups (HR: 1.03; 95% CI 0.64-1.47, P = 0.873). African/Afro-Caribbean men on AS for PCa in the UK are less likely to adhere to scheduled appointments, suggesting a more tailored service addressing their specific needs may be required. While African/Afro-Caribbean men were no more likely to convert to treatment than Caucasian/other men, findings of a potentially higher risk of disease progression signal the need for careful selection and monitoring of African/Afro-Caribbean men on AS. Larger prospective, multicentre studies with longer follow-up are required to provide more definitive conclusions.
Sections du résumé
BACKGROUND
Experiences of African/Afro-Caribbean men on active surveillance (AS) for prostate cancer (PCa) in the United Kingdom (UK) are not well documented. We compared follow-up appointments, adherence, and clinical outcomes among African/Afro-Caribbean men on AS at a high-volume UK hospital with other ethnicities.
METHODS
Men with confirmed low-intermediate risk Pca who attended the AS clinic (2005-2016) and had undergone ≥1 follow-up biopsy (n = 458) were included. Non-adherence (defined as >20% missed appointments), suspicion of disease progression (any upgrading, >30% positive cores, cT-stage > 3, PIRADS > 3), any upgrading from diagnostic biopsy and conversion to active treatment (prostatectomy, radiotherapy or hormone therapy) according to ethnicity (African/Afro-Caribbean versus other ethnicities) were assessed using multivariable regression analysis.
RESULTS
Twenty-three percent of eligible men were recorded as African/Afro-Caribbean, while the remainder were predominantly Caucasian. African/Afro-Caribbean men had slightly lower PSA at diagnosis (median 5.0 vs. 6.0 ng/mL) and more positive cores at diagnosis (median 2 vs. 1). They had a substantially higher rate of non-attendance at scheduled follow-up visits (24% vs. 10%, p < 0.001). Adjusted analyses suggest African/Afro-Caribbean men may be at increased risk of disease progression (hazard ratio [HR]: 1.38; 95% confidence interval [CI] 0.99-1.91, P = 0.054) and upgrading (HR: 1.29; 95% CI 0.87-1.92, P = 0.305), though neither reached statistical significance. No difference in risk of conversion to treatment was observed between ethnic groups (HR: 1.03; 95% CI 0.64-1.47, P = 0.873).
CONCLUSIONS
African/Afro-Caribbean men on AS for PCa in the UK are less likely to adhere to scheduled appointments, suggesting a more tailored service addressing their specific needs may be required. While African/Afro-Caribbean men were no more likely to convert to treatment than Caucasian/other men, findings of a potentially higher risk of disease progression signal the need for careful selection and monitoring of African/Afro-Caribbean men on AS. Larger prospective, multicentre studies with longer follow-up are required to provide more definitive conclusions.
Identifiants
pubmed: 33558659
doi: 10.1038/s41391-020-00313-0
pii: 10.1038/s41391-020-00313-0
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
549-557Références
Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003;91:789–94.
doi: 10.1046/j.1464-410X.2003.04232.x
U.S. Cancer Statistics Working Group. Prostate cancer rates by race and ethnicity 1999–2014. 2014. Available from: https://www.cdc.gov/cancer/prostate/statistics/race.htm .
Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, et al. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur Urol. 2008;53:99–105.
doi: 10.1016/j.eururo.2007.02.047
Chinegwundoh F, Enver M, Lee A, Nargund V, Oliver T, Ben-Shlomo Y. Risk and presenting features of prostate cancer amongst African-Caribbean, South Asian and European men in North-east London. BJU Int. 2006;98:1216–20.
doi: 10.1111/j.1464-410X.2006.06503.x
Jack RH, Davies EA, Moller H. Prostate cancer incidence, stage at diagnosis, treatment and survival in ethnic groups in South–East England. BJU Int. 2010;105:1226–30.
doi: 10.1111/j.1464-410X.2009.08940.x
Mahal BA, Berman RA, Taplin ME, Huang FW. Prostate cancer-specific mortality across Gleason scores in black vs nonblack men. JAMA. 2018;320:2479–81.
doi: 10.1001/jama.2018.11716
Karami S, Young HA, Henson DE. Earlier age at diagnosis: another dimension in cancer disparity? Cancer Detect Prev. 2007;31:29–34.
doi: 10.1016/j.cdp.2006.11.004
Metcalfe C, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, et al. Pathways to diagnosis for Black men and White men found to have prostate cancer: the PROCESS cohort study. Br J Cancer. 2008;99:1040–5.
doi: 10.1038/sj.bjc.6604670
Kim HS, Moreira DM, Jayachandran J, Gerber L, Banez LL, Vollmer RT, et al. Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. Prostate Cancer Prostatic Dis. 2011;14:262–5.
doi: 10.1038/pcan.2011.18
Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010;183:1792–6.
doi: 10.1016/j.juro.2010.01.015
Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating Black–White differences in prostate cancer prognosis: a systematic review and meta-analysis. Int J Cancer. 2008;123:430–5.
doi: 10.1002/ijc.23500
Evans S, Metcalfe C, Patel B, Ibrahim F, Anson K, Chinegwundoh F, et al. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study. Br J Cancer. 2010;102:249–54.
doi: 10.1038/sj.bjc.6605461
National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management, NICE Guideline [NG131]. 2019. Available from: https://www.nice.org.uk/guidance/ng131/chapter/Recommendations#assessment-and-diagnosis .
Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–22.
doi: 10.1016/S0140-6736(16)32401-1
Dall’Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62:976–83.
doi: 10.1016/j.eururo.2012.05.072
Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010;28:1069–74.
doi: 10.1200/JCO.2009.26.2469
Lewisham PH. Lewisham’s joint strategic needs assessment: index of multiple deprivation. 2010. Available from: http://www.lewishamjsna.org.uk/health-inequities/index-of-multiple-deprivation.
Statistics DoCaLGOoN. The English indices of deprivation. 2015. Available from: http://www.gov.uk/government/statistics/english-indices-of-deprivation-2015 .
Trust of London. Poverty and inequity data for Southwark. 2020. Available from: https://www.trustforlondon.org.uk/data/boroughs/southwark-poverty-and-inequaty-indicators/ .
Du XL, Fang S, Coker AL, Sanderson M, Aragaki C, Cormier JN, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer. 2006;106:1276–85.
doi: 10.1002/cncr.21732
Kheirandish P, Chinegwundoh F. Ethnic differences in prostate cancer. Br J Cancer. 2011;105:481–5.
doi: 10.1038/bjc.2011.273
Graham-Steed T, Uchio E, Wells CK, Aslan M, Ko J, Concato J. ‘Race’ and prostate cancer mortality in equal-access healthcare systems. Am J Med. 2013;126:1084–8.
doi: 10.1016/j.amjmed.2013.08.012
Exarchakou A, Rachet B, Belot A, Maringe C, Coleman MP. Impact of national cancer policies on cancer survival trends and socioeconomic inequalities in England, 1996–2013: population based study. BMJ. 2018;360:k764.
doi: 10.1136/bmj.k764
Veugelers PJ, Yip AM. Socioeconomic disparities in health care use: does universal coverage reduce inequalities in health? J Epidemiol Community Health. 2003;57:424–8.
doi: 10.1136/jech.57.6.424
Fazil Q. Better health briefing 47: cancer and black and ethnic communities. A race equality foundation briefing paper. 2018. Available from: http://raceequalityfoundation.org.uk/wp-content/uploads/2018/07/REF-better-health-471-1.pdf .
Prostate Cancer UK. ‘Check it out’ prostate cancer support group for African and African Caribbean men. 2019. Available from: https://prostatecanceruk.org./get-support/find-local-support/check-it-out-prostate-cancer-support-group.
Casey RG, Powell L, Braithwaite M, Booth CM, Sizer B, Corr JG. Nurse-led phone call follow-up clinics are effective for patients with prostate cancer. J Patient Exp. 2017;4:114–20.
doi: 10.1177/2374373517706613
Anderson B. The benefits to nurse-led telephone follow-up for prostate cancer. Br J Nurs. 2010;19:1085–90.
doi: 10.12968/bjon.2010.19.17.78565
Wasson J, Gaudette C, Whaley F, Sauvigne A, Baribeau P, Welch HG. Telephone care as a substitute for routine clinic follow-up. JAMA. 1992;267:1788–93.
doi: 10.1001/jama.1992.03480130104033
Kinsella N, Beckmann K, Cahill D, Elhage O, Popert R, Cathcart P, et al. A single educational seminar increases confidence and decreases dropout from active surveillance by 5 years after diagnosis of prostate cancer. Eur. Urol Oncol. 2019;2:464–70.
doi: 10.1016/j.euo.2018.09.007
Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelson A, Bratt O, et al. Factors influencing men’s choice of and adherence to active surveillance for low-risk prostate cancer: a mixed-method systematic review. Eur Urol. 2018;74:261–80.
doi: 10.1016/j.eururo.2018.02.026
Formica MK, Wason S, Seigne JD, Stewart TM. Impact of a decision aid on newly diagnosed prostate cancer patients’ understanding of the rationale for active surveillance. Patient Educ Couns. 2017;100:812–7.
doi: 10.1016/j.pec.2016.11.019
Kinsella N, Helleman J, Bruinsma S, Carlsson S, Cahill D, Brown C, et al. Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol. 2018;7:83–97.
doi: 10.21037/tau.2017.12.24